A Carlyle Group-managed fund has completed its acquisition of Baxter International’s Kidney Care business, establishing Vantive as a newly independent company specializing in renal and vital organ therapy, including in Korea.
“Building on over 70 years of leadership and innovation in kidney care, Vantive is committed to advancing the treatment of vital, life-sustaining organs. Our mission is 'Extending Lives, Expanding Possibilities,' providing more flexible, collaborative, and accessible treatment options for patients and healthcare professionals,” said Im Kwang-hyuk, general manager of Vantive Korea, in a LinkedIn post on Tuesday.
To support its operations, Vantive Korea has relocated its office to Cheonggyecheon-ro near Gwanghwamun, Seoul, to create a more efficient working environment.
Vantive aims to expand access to dialysis and life-sustaining organ therapy while improving treatment standards. The company estimates that about four million people worldwide receive dialysis for chronic kidney disease. Access to treatment, however, varies widely, and patients often face significant physical and emotional burdens.
As an independent entity, Vantive plans to address these disparities by reducing barriers to care and equipping patients and healthcare providers with more control over treatment options.
Chris Toth, Vantive’s CEO, emphasized the company’s focus on providing timely and effective care. “It is crucial to offer better choices, greater autonomy, and expanded possibilities for patients starting dialysis and for medical professionals working to save lives in intensive care units,” Toth said.
“Vantive is ushering in a new era of innovation in life-sustaining organ therapy, and alongside our 23,000 employees worldwide, we are dedicated to making a meaningful impact on millions of patients and their families,” he added.
Vantive develops dialysis solutions for home and hospital use, along with digital tools and advanced treatment options for critically ill patients. The company’s technologies are used over one million times daily in more than 100 countries, and Vantive said it sees each interaction as an opportunity to refine care delivery and improve patient outcomes.
The company aims to streamline treatment with integrated medical equipment, allowing healthcare professionals to work more efficiently while enabling patients to maintain their daily lives. Its technology is designed to enhance treatment outcomes and reduce inefficiencies.
“Digital patient management tools used in home dialysis, for example, have been shown to lower mortality rates, reduce hospitalizations, and improve long-term adherence to home-based therapy,” a Vantive official said.
Related articles
- Baxter Korea highlights clinical, environmental benefits of HDx therapy at symposium
- Baxter updates home peritoneal dialysis management app MyPD
- Samsung Biologics secures $223 million contract with Baxter Healthcare
- Baxter launches ‘MyPD,’ a digital management app for peritoneal dialysis patients
- Viatris, Pfizer, Vantive cut jobs in Korea
- Korea faces decline in peritoneal dialysis adoption despite growing global trend
- Baxter launches Progressa ICU bed in Korea with early rehab features
- Post-Baxter, Vantive targets Korea’s kidney crisis with digital home strategy, eyes liver and lung care next
- Vantive Korea pushes to boost home peritoneal dialysis use
